The market has been down on Actinium Pharmaceuticals Inc (ATNM) stock recently. ATNM gets a Bearish score from InvestorsObserver's Stock Sentiment Indicator.
What is Stock Sentiment?
When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment.
Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive.
InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend.
Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .
What's Happening With ATNM Stock Today?
Actinium Pharmaceuticals Inc (ATNM) stock is trading at $7.98 as of 12:17 PM on Thursday, Dec 31, a drop of -$0.18, or -2.21% from the previous closing price of $8.16. The stock has traded between $7.94 and $8.30 so far today. Volume today is 476,463 compared to average volume of 567,778.
To screen for more stocks like Actinium Pharmaceuticals Inc click here.
More About Actinium Pharmaceuticals Inc
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of innovative-targeted therapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells safely and effectively. Its most advanced products are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.
Click Here to get the full Stock Score Report on Actinium Pharmaceuticals Inc (ATNM) Stock.
